Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Biomed Res Int. 2020 Nov 6;2020:5487659. doi: 10.1155/2020/5487659. eCollection 2020.
Treating nonalcoholic fatty liver disease (NAFLD) is considered one of the public health priorities in the past decade. So far, probiotics have represented promising results in controlling the signs and symptoms of NAFLD. However, attempts to find the ideal probiotic strain are still ongoing. The present study is designed to find the best strain amongst suitable probiotic strains according to their ability to ameliorate histopathological and oxidative stress biomarkers in hepatic steatosis-induced rats.
Initially, four probiotics species, including () , , , and , were cultured and prepared as a lyophilized powder for animals. The experiment lasted for fifty days. Initially, hepatic steatosis was induced by excessive ingestion of D-fructose in rats for eight weeks, followed by eight weeks of administering probiotics and D-fructose concurrently. Forty-two six-week-old male rats were alienated to different groups and were supplemented with different probiotics (1∗10 CFU in 500 mL drinking water). After eight weeks, blood and liver samples were taken for further evaluation, and plasma and oxidative stress markers corresponding to liver injuries were examined.
Administration of probiotics over eight weeks reversed hepatic and blood triglyceride concentration and blood glucose levels. Also, probiotics significantly suppressed markers of oxidative stress in the liver tissue.
Although some of the single probiotic formulations were able to mitigate oxidative stress markers, mixtures of probiotics significantly ameliorated more symptoms in the NAFLD animals. This enhanced effect might be due to probiotics' cumulative potential to maintain oxidative stress and deliver improved lipid profiles, liver function markers, and inflammatory markers.
在过去十年中，治疗非酒精性脂肪性肝病 (NAFLD) 被认为是公共卫生重点之一。到目前为止，益生菌在控制 NAFLD 的体征和症状方面已经取得了有希望的结果。然而，寻找理想的益生菌菌株的尝试仍在继续。本研究旨在根据其改善肝脂肪变性诱导大鼠组织病理学和氧化应激生物标志物的能力，从合适的益生菌菌株中找到最佳菌株。
最初，培养了四种益生菌物种，包括 ()、、、和，并用冻干粉末为动物准备。实验持续了五十天。最初，通过让大鼠过量摄入 D-果糖八周来诱导肝脂肪变性，然后再用益生菌和 D-果糖同时给药八周。将 42 只六周龄雄性大鼠分为不同组，并补充不同的益生菌（1*10CFU 在 500mL 饮用水中）。八周后，采集血液和肝脏样本进行进一步评估，并检查与肝损伤相关的血浆和氧化应激标志物。
八周的益生菌给药逆转了肝和血液甘油三酯浓度以及血糖水平。此外，益生菌还显著抑制了肝组织中的氧化应激标志物。
虽然一些单一的益生菌配方能够减轻氧化应激标志物，但益生菌混合物显著改善了 NAFLD 动物的更多症状。这种增强的效果可能是由于益生菌累积的维持氧化应激和改善脂质谱、肝功能标志物和炎症标志物的潜力。
